<DOC>
	<DOCNO>NCT02848001</DOCNO>
	<brief_summary>CC-90009-AML-001 phase 1 , open-label , dose escalation expansion , study subject relapse refractory acute myeloid leukemia</brief_summary>
	<brief_title>A Dose-finding Study CC-90009 Subjects With Relapsed Refractory Acute Myeloid Leukemia</brief_title>
	<detailed_description>Study CC-90009-AML-001 open-label , Phase 1 , dose escalation expansion , first-in-human clinical study CC-90009 subject relapse refractory acute myeloid leukemia ( AML ) . The dose escalation part ( Part A ) study evaluate safety tolerability escalate dos CC-90009 , The expansion part ( Part B ) evaluate safety efficacy CC-90009 administer maximum tolerate dose ( MTD ) select expansion cohort order determine recommend Phase 2 dose ( RP2D ) .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<criteria>1 . Men woman ≥ 18 year age , time sign ICD ( Informed Consent Document ) . 2 . Subject must understand voluntarily sign ICD prior studyrelated assessments/procedures conduct . 3 . Relapsed refractory AML ( Acute Myeloid Leukemia ) define World Health Organization criterion suitable establish therapy . 4 . Eastern Cooperative Oncology Group Performance Status ( ECOG PS ) 0 2 . 5 . At least 4 week ( first dose ) elapse donor lymphocyte infusion ( DLI ) without condition . 6 . Subjects must follow screen laboratory value : Total White Blood Cell count ( WBC ) &lt; 25 x 109/L prior first infusion . Prior concurrent treatment hydroxyurea achieve level allow . Selected electrolyte within normal limit correctable supplement . Serum bilirubin ≤ 1.5 x ULN ( upper limit normal ) . Estimated serum creatinine clearance ≥ 60 mL/min use CockcroftGault equation . 7 . Agree follow CC90009 Pregnancy Prevention Plan ( PPP ) 1 . Subjects acute promyelocytic leukemia ( APL ) 2 . Subjects clinical symptom suggest active central nervous system ( CNS ) leukemia know CNS leukemia . Evaluation cerebrospinal fluid require clinical suspicion CNS involvement leukemia screen . 3 . Patients prior autologous hematopoietic stem cell transplant , investigator 's judgment , fully recover effect last transplant ( e.g. , transplant related side effect ) . 4 . Prior allogeneic hematopoietic stem cell transplant ( HSCT ) either standard reduce intensity condition ≤ 6 month prior start CC90009 . 5 . Subjects systemic immunosuppressive therapy post HSCT time screening , clinically significant graftversushost disease ( GVHD ) . The use topical steroid ongoing skin ocular GVHD permit . 6 . Prior systemic cancerdirected treatment investigational modality ≤ 5 half live 4 week prior start CC90009 , whichever short . Hydroxyurea allow control peripheral leukemia blast . 7 . Leukapheresis ≤ 2 week prior start CC90009 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>CC-90009</keyword>
	<keyword>Hematologic Cancers</keyword>
	<keyword>Leukemia</keyword>
	<keyword>Acute Myeloid Leukemia</keyword>
</DOC>